NASDAQ:HRMY

Harmony Biosciences Holdings Stock News

etoro logo Buy HRMY
*Your capital is at risk
$35.24
-0.620 (-1.73%)
At Close: Jul 31, 2026
WAKIX® (pitolisant) Net Revenue of $168.4 Million for Fourth Quarter and $582.0 Million for Full Year 2023; Representing Growth of ~31% and ~33%, Respectively
Prescription Drug User Fee Act date is June 21, 2024 PLYMOUTH MEETING, Pa., Feb. 21, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced that the U.S. Food and Drug Admini
PLYMOUTH MEETING, Pa. , Feb. 20, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation
There are many types of companies in the financial markets, firstly from different sectors, and secondly, they can vary according to their capitalization size. Their capitalization can go by various f
PLYMOUTH MEETING, Pa. , Feb. 8, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report fourth quarter and full year 2023 financial results on Thurs
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two stocks present
When it comes to undervalued Russell 2000 stocks, the narrative for targeting this specific space is the same as any other market-based motivation: buy low, sell high. It's just that with the Russell
The mean of analysts' price targets for Harmony Biosciences Holdings, Inc. (HRMY) points to a 28.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, stro
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Repligen (RGEN). But which of these two st
Harmony Biosciences Holdings, Inc. (HRMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate
The average of price targets set by Wall Street analysts indicates a potential upside of 32.2% in Harmony Biosciences Holdings, Inc. (HRMY). While the effectiveness of this highly sought-after metric
Harmony Biosciences Holdings, Inc. (HRMY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or Acadia Pharmaceuticals (ACAD). But which of thes
PLYMOUTH MEETING, Pa. , Jan. 3, 2024 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializin

Why Harmony Biosciences Stock Got Slammed Today

06:38pm, Tuesday, 02'nd Jan 2024
An analyst downgraded his recommendation on the biotech. He now rates it as a sell, where previously he felt it was a neutral.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE